Karyopharm Therapeutics (KPTI) Other Non-Current Assets (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Other Non-Current Assets came in at $267000.0 in Q4 2025, down 79.99% YoY from $1.3 million in Q4 2024, and down 23.71% on a QoQ basis from $350000.0 in Q3 2025.
Karyopharm Therapeutics (KPTI) Other Non-Current Assets (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Other Non-Current Assets data on file, last reported at $267000.0 in Q4 2025.
- Quarterly Other Non-Current Assets fell 79.99% year-over-year to $267000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $267000.0 (down 79.99% YoY) and the FY2025 annual result came in at $267000.0, down 79.99% from the prior year.
- Other Non-Current Assets slipped to $267000.0 in Q4 2025, from $350000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $1.3 million in Q4 2024 to a low of $267000.0 in Q4 2025.
- A 5-year average of $520850.0 and a median of $506500.0 in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets surged 343.19% — and 2025, when it slumped 79.99%.
- Tracing KPTI's Other Non-Current Assets over 5 years: stood at $637000.0 in 2021, then dropped by 0.63% to $633000.0 in 2022, then tumbled by 52.45% to $301000.0 in 2023, then surged by 343.19% to $1.3 million in 2024, then tumbled by 79.99% to $267000.0 in 2025.
- The last three Other Non-Current Assets figures came in at $267000.0 (Q4 2025), $350000.0 (Q3 2025), and $350000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | 318,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 318,000.00 |
| Dec 31, 2025 | 267,000.00 |
| Sep 30, 2025 | 350,000.00 |
| Jun 30, 2025 | 350,000.00 |
| Mar 31, 2025 | 340,000.00 |
| Dec 31, 2024 | 1.33 Mn |
| Sep 30, 2024 | 306,000.00 |
| Jun 30, 2024 | 304,000.00 |
| Mar 31, 2024 | 304,000.00 |
| Dec 31, 2023 | 301,000.00 |
| Sep 30, 2023 | 381,000.00 |
| Jun 30, 2023 | 387,000.00 |
| Mar 31, 2023 | 634,000.00 |
| Dec 31, 2022 | 633,000.00 |
| Sep 30, 2022 | 626,000.00 |
| Jun 30, 2022 | 631,000.00 |
| Mar 31, 2022 | 636,000.00 |
| Dec 31, 2021 | 637,000.00 |
| Sep 30, 2021 | 639,000.00 |
| Jun 30, 2021 | 639,000.00 |